Comparing the difference of adverse events with HER2 inhibitors: a study of the FDA adverse event reporting system (FAERS)

Overview of attention for article published in Frontiers in Pharmacology, January 2024

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 3 Dimensions

Readers on

mendeley: 2 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 3 publications that cite this research output.

3

The most recent citing publications are shown below. View all 3 publications that cite this research output on Dimensions.

Multidimensional assessment of adverse events of finasteride: a real-world pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS) from 2004 to April 2024

Preprint in medRxiv (August 2024)

Adverse event profile of memantine and donepezil combination therapy: a real-world pharmacovigilance analysis based on FDA adverse event reporting system (FAERS) data from 2004 to 2023

Article in Frontiers in Pharmacology (July 2024)

Cardioprotective effects of Platycodon grandiflorum Granules in HER2-positive early breast cancer patients receiving Trastuzumab plus Pertuzumab: study protocol for a double blind randomized controlled trial

Preprint in Research Square (June 2024)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.